The U.S. is recommending a “pause” in the administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. This, after six people in the U.S. developed a rate blood clotting disorder following the vaccine.
The FDA is making the recommendation “out of an abundance of caution,” adding that the blood clotting in just a handful of recipients is extremely rare.
— U.S. FDA (@US_FDA) April 13, 2021
In a joint statement with the Centers for Disease Control and Prevention, the FDA said, “COVID-19 vaccine safety is a top priority for the federal government and we take all reports of health problems very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the statement read.
Shares of Johnson & Johnson were down nearly 3% in pre-market trading on Tuesday after closing up in Monday’s session.